Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B

Fig. 1

RhoBTBs differentially control METTL7 expression. a HeLa cells were transfected with siRNAs targeting RhoBTB1 or RhoBTB2, or the lamin siRNA control. Two independent siRNAs were used for each target. The efficiency of these siRNAs in HeLa cells was quantified in our previous study [16]. After 48 h, RNA was prepared from the cells and the expression of METTL7A was quantified by RT-PCR. Silencing of RhoBTB2 significantly reduced the expression of METTL7A. b Expression of METTL7B was quantified in the same samples. Silencing of RhoBTB1 significantly reduced the expression of METTL7B. Data are means ± SEM (n = 3). Data were normalized to mock-transfected HeLa cells. Comparisons are to the lamin siRNA control; *P <0.05, **P <0.01, ****P <0.0001

Back to article page